This project has been funded in whole or in part with Federal funds from the National Library of Medicine, National Institutes of Health, Department of Health and Human Services, under Contract No. HHS-N-276-2011-00003-C with the University of Pittsburgh-Health Sciences Library System.
A Podcast by John Campbell
The information on the internet is massive and we need to know how to distinguish the trustworthy ones especially when we are surfing for health information.
Firstly, ask yourself these questions:
♦ Why did the person create the page?
♦ What's in it for them?
♦ Are they trying to sell me something?
Next, follow the National Network of Libraries of Medicine (NN/LM) criteria for evaluating health websites below:
♦ Bias/ Objectivity
♦ Currency/ Timelines
For viewing the complete information please go to NN/LM
Have you downloaded the new Parkinson’s Central Smartphone App onto your iPhone or Android phone?
Parkinson’s Central by National Parkinson Foundation, Inc. is an app meant to bring information to those living with Parkinson’s Disease, or to those who are living with someone with PD. It is designed to answer any questions you may have regarding the disease, its treatment, and more.
Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand, and the symptoms worsen as the condition progresses over time.
Parkinson's disease symptoms and signs may vary from person to person including:
Environmental triggers (Exposure to certain toxins or environmental factors)
Age: It usually begins in middle or late life, and the risk continues to increase with age.
Heredity: Having a close relative with Parkinson's disease increases the chances that one could develop the disease.
Sex: Men are more likely to develop Parkinson's disease than are women.
Exposure to toxins: Constant exposure to herbicides and pesticides could slightly increase risk of Parkinson's disease.
FDA Approval of RYTARY (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease
Impax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease.
To find out more click here.
National Parkinson Foundation has developed a page for patients to share their personal experiences. The stories are very inspiring and illustrate the challenges, triumphs and learning moments of those living with Parkinson's disease.
To browse the stories click here.
To share your story with the Parkinson.org community, complete the online form.